Frank Boess
YOU?
Author Swipe
View article: At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact
At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact Open
Once-weekly subcutaneous home administration of the anti-amyloid-beta antibody gantenerumab by non-healthcare-professional care partners to participants with early Alzheimer's disease was feasible, safe, well tolerated, and considered as a…
View article: Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab
Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab Open
Background The Q‐ATN model (Mazer et al., Alzheimer’s & Dementia. 2022; https://doi.org/10.1002/alz/12877 ) is a quantitative semi‐mechanistic representation of the A (amyloid)/T (tau)/N (neurodegeneration) framework for simulating the nat…
View article: Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model)
Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model) Open
Introduction A quantitative model of Alzheimer's disease (AD) based on the amyloid/tau/neurodegeneration biomarker framework (Q‐ATN model) was developed to sequentially link amyloid positron emission tomography (PET), tau PET, medial tempo…
View article: Trial of Prasinezumab in Early-Stage Parkinson’s Disease
Trial of Prasinezumab in Early-Stage Parkinson’s Disease Open
Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann-La Roche and Prothena Biosciences; P…
View article: A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data Open
Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. Objective: The study objective was to evaluate the efficacy and…
View article: A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design and baseline data
A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design and baseline data Open
Background Currently available treatments for Parkinson’s disease (PD) do not slow clinical progression nor target alpha-synuclein, the main pathology associated with the disease. Objective The study objective was to evaluate the efficacy …
View article: Treatment Patterns in Patients with Incident Parkinson’s Disease in the United States
Treatment Patterns in Patients with Incident Parkinson’s Disease in the United States Open
Time from diagnosis to treatment start was relatively short, suggesting that PD diagnosis, as reflected in the database, is closely linked to start of symptomatic treatment. Levodopa treatment remains the most common treatment, especially …
View article: Progressive Decline in Gray and White Matter Integrity in de novo Parkinson’s Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data
Progressive Decline in Gray and White Matter Integrity in de novo Parkinson’s Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data Open
Background: Progressive neuronal loss in neurodegenerative diseases such as Parkinson's disease (PD) is associated with progressive degeneration of associated white matter tracts as measured by diffusion tensor imaging (DTI). These finding…
View article: Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease Open
ClinicalTrials.gov Identifier: NCT02157714.
View article: Characterization of 3 Novel Tau Radiopharmaceuticals, <sup>11</sup> C-RO-963, <sup>11</sup> C-RO-643, and <sup>18</sup> F-RO-948, in Healthy Controls and in Alzheimer Subjects
Characterization of 3 Novel Tau Radiopharmaceuticals, <sup>11</sup> C-RO-963, <sup>11</sup> C-RO-643, and <sup>18</sup> F-RO-948, in Healthy Controls and in Alzheimer Subjects Open
11C-RO-963, 11C-RO-643, and 18F-RO-948 (previously referred to as 11C-RO6924963, 11C-RO6931643, and 18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here w…
View article: Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial
Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial Open
Background : Ubiquitous digital technologies such as smartphone sensors promise to fundamentally change biomedical research and treatment monitoring in neurological diseases such as PD, creating a new domain of digital biomarkers. Objectiv…
View article: First in-human PET study of 3 novel tau radiopharmaceuticals: [<sup>11</sup>C]RO6924963, [<sup>11</sup>C]RO6931643, and [<sup>18</sup>F]RO6958948
First in-human PET study of 3 novel tau radiopharmaceuticals: [<sup>11</sup>C]RO6924963, [<sup>11</sup>C]RO6931643, and [<sup>18</sup>F]RO6958948 Open
Background [ 11 C]RO-963, [ 11 C]RO-643 and [ 18 F]RO-948 (previously referred as [ 11 C]RO6924963, [ 11 C]RO6931643, and [ 18 F]RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and pre…